Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
(Thomson Reuters ONE) -
LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar
Therapeutics plc ("Nightstar" or the "Company") (NASDAQ:NITE), a clinical-stage
gene therapy company developing treatments for rare inherited retinal diseases,
today announced the closing of its previously announced initial public offering
in the United States of 6,164,000 American Depositary Shares ("ADSs")
representing 6,164,000 ordinary shares, at an initial public offering price of
$14.00, which includes an additional 804,000 ADSs issued upon the exercise in
full by the underwriters of their option to purchase additional ADSs. Aggregate
net proceeds to the Company, after underwriting discounts and commissions and
estimated offering expenses payable by the Company, will be approximately $76.9
million. All of the ADSs were offered by Nightstar.
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. acted as joint
book-running managers for the offering. Wedbush Securities Inc. and Chardan
acted as co-managers.
The offering was made only by means of a prospectus. A copy of the prospectus
relating to the offering was filed with the U.S. Securities and Exchange
Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by
telephone at (877) 547-6340, or by email at Prospectus_Department(at)Jefferies.com;
Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or by
email at Syndicate(at)Leerink.com; or BMO Capital Markets Corp., Attention: Equity
Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at
(800) 414-3627, or by email at bmoprospectus(at)bmo.com.
A registration statement relating to these securities has been filed with, and
declared effective by, the U.S. Securities and Exchange Commission. This press
release does not constitute an offer to sell or the solicitation of an offer to
buy securities, and shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of that jurisdiction.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on developing
and commercializing novel one-time treatments for patients suffering from rare
inherited retinal diseases including choroideremia, X-linked retinitis
pigmentosa and Best vitelliform macular dystrophy.
Contact:
Senthil Sundaram, Chief Financial Officer
investors(at)nightstartx.com
Alicia Davis, THRUST IR
910-620-3302
alicia(at)thrustir.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nightstar Therapeutics via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 562139
Anzahl Zeichen: 3489
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Nightstar Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
